—Classifying myelodysplastic syndrome and secondary acute myeloid leukemia by genetic mutations rather than strictly by blast count may allow more patients to be eligible for AML and MDS clinical ...

Panelists discuss how current risk stratification systems, particularly the European Leukemia Net 2022 classification for intensive therapy and the 2024 classification for lower intensity treatments, ...

New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...

•Genomic characterization determines diagnosis, classification, and prognostication of the myeloid malignancies myelodysplastic syndrome (MDS) and AML. •Recognizing genetic lesions as invariable ...

In order to better treat patients diagnosed with acute myeloid leukaemia (AML), researchers need to understand the pathological processes and distinguish between different subgroups of the disease.

Researchers have discovered the first proteomic subtype of an aggressive blood cancer by using mass spectrometry technology. In order to better treat patients diagnosed with acute myeloid leukemia ...